Streamlined genetic disease workflows that power labs for growth
Current tools for rare variant analysis are fragmented, often involving several different pipelines that all require separate integration efforts and maintenance schedules. This disjointed framework prevents laboratories from scaling services effectively. Today, high-throughput labs need intuitive tools for variant calling, interpretation, and reporting in a comprehensive and seamless way.
The TruSight Software Suite consolidates all these tools at your fingertips. Simplify rare variant analysis and interpretation by calling, prioritizing, and reporting on variants from one software interface. The suite is designed for high-throughput labs using whole-genome sequencing to evaluate and report on variants associated with rare genetic disease.
Learn More about TruSight Software SuiteDeveloped with input from leaders in genome interpretation of rare disease, the TruSight Software Suite annotates variants and genes from multiple public databases, such as ClinVar, OMIM, and gnomAD. Additional options to upload custom annotations and query aggregated cases with CaseLog help you leverage institutional knowledge and learn from previous findings.
TruSight Software Suite also includes variant prioritization tools, including machine learning-based tools, to help corroborate results and sort on key variants. With intuitive interpretation and reporting options, you can filter variants via gene lists, inheritance modes, custom annotations, complex logic, and more.
Save time and avoid the fragmented, multi-tool workflows common in rare variant analysis. The TruSight Software Suite supports seamless integration into an Illumina sequencing workflow, from accession to final reports. Jumpstart an automated analysis and interpretation pipeline and manage a single proband or up to five relatives within a single interface.
Centralizing multiple interpretation tools allows for consistent, robust compliance. TruSight Software Suite is ISO-27001 and ISO-13485 certified and complies with HIPAA (third party audited) and the principles of the GDPR. We also offer options to integrate with your lab’s single sign-on policy and other security settings.
Current tools for rare-genetic and other germline variant analysis are fragmented, often involving several pipelines requiring separate integration efforts and maintenance schedules. This disjointed framework prevents laboratories from scaling services effectively. Today, high-throughput labs need intuitive tools for variant calling, insights generation and interpretation support, and reporting in a comprehensive and seamless way.
Emedgene, integrated with DRAGEN, consolidates all these functions at your fingertips. Simplify rare variant analysis and interpretation for research applications by calling, prioritizing, and reporting on variants from a single software interface within a connected workflow. Emedgene is ideal for mid to high-throughput labs using whole-genome, whole-exome, and targeted or virtual panel sequencing to evaluate variants and generate insights associated with genetic disease.
Learn more about DRAGEN Secondary Analysis to support comprehensive, accurate, and efficient variant calling.
Learn more about Emedgene to integrate with DRAGEN and to streamline variant interpretation through research report generation.
Find critical answers quickly with comprehensive variant calling and interpretation.
Most accurate secondary analysis in all-benchmark regions, as compared against all participating solutions in F1 score using PrecisionFDA v2 Truth Challenge Benchmark Data
DRAGEN secondary analysis provides highly accurate rare variant calling and analysis, with automated processing and rapid turnaround time. Powered by the DRAGEN multigenome (graph) reference and machine learning (ML), the suite performs accurate, comprehensive, and efficient identification for key variant types and capabilities, including:
By analyzing and visualizing multiple types at one time, you can easily view compound heterozygosity across variant categories. DRAGEN v4.2 functionalities are now available on Emedgene for integrated rare variant analysis and interpretation.
Emedgene was designed by geneticists to streamline interpretation workflows and reduce the variant curation burden. It features an automated, explainable-AI (XAI)–powered genomic analysis platform that enables high-throughput interpretation with a 2–5x increase in efficiency and 50–75% reduction in total workflow time per subject.
Never a black box. Emedgene’s XAI prioritizes putative causative variants, backed by transparent evidence, to increase workflow efficiency and confidence. In a study with Baylor Genetics*, Emedgene’s XAI was shown to be 97% accurate (98% for trios) in prioritizing relevant insights. Highly accurate and transparent, XAI can automatically suggest variants for further review in complex data sets that would typically require hours of manual research.
Dr. Ray Louie, PhD
Assistant Director, Greenwood Genetic Center
By integrating with secondary analysis solutions such as DRAGEN™, data storage platforms such as Illumina Connected Analytics, and electronic health record (EHR) platforms, Emedgene offers a seamless and secure solution from sequencing through research report generation and beyond.
Emedgene scales WGS, WES, targeted panels, and virtual panels for variant interpretation across applications and variant types: single nucleotide variants (SNVs), insertions/deletions (indels), copy number variants (CNVs), mitochondrial DNA variants (mtDNA), structural variants (SVs), and short tandem repeats (STRs).
DRAGEN secondary analysis enables GeneDx to scale to whole-genome analysis and identify variants with precision.
Read ArticleThe Medical Genome Initiative consortium aims to expand access to high-quality clinical whole-genome sequencing for rare genetic diseases.
Read ArticleA randomized clinical trial examines the effect of whole-genome sequencing on the clinical management of acutely ill infants with suspected genetic disease.
Read ArticleWhole-genome sequencing is the most comprehensive test for rare disease, with the potential with the potential to uncover new breakthroughs in disease causality.
Learn MoreWhole Exome Sequencing is used to investigate protein-coding regions of the genome to uncover genetic influences on disease and population health.
Learn MoreOur technology is helping to drive breakthroughs in genetic disease research by facilitating faster insights.
Learn MoreHigh performance for sensitive applications such as human whole-genome sequencing.
Get scalable throughput and flexibility for virtually any sequencing method, genome, and scale of project.
Perform accurate, comprehensive, and efficient analysis of next-generation sequencing data.